Ninety One North America Inc. Makes New Investment in Boston Scientific Corporation $BSX

Ninety One North America Inc. acquired a new position in Boston Scientific Corporation (NYSE:BSX) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 77,718 shares of the medical equipment provider’s stock, valued at approximately $7,410,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Crown Wealth Group LLC boosted its position in Boston Scientific by 4.7% in the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after purchasing an additional 100 shares during the last quarter. Claret Asset Management Corp boosted its position in Boston Scientific by 4.4% in the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 102 shares during the last quarter. Cary Street Partners Investment Advisory LLC boosted its position in Boston Scientific by 5.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 103 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors boosted its position in Boston Scientific by 2.3% in the third quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 4,776 shares of the medical equipment provider’s stock worth $466,000 after purchasing an additional 108 shares during the last quarter. Finally, Kera Capital Partners Inc. raised its stake in shares of Boston Scientific by 3.3% in the third quarter. Kera Capital Partners Inc. now owns 3,407 shares of the medical equipment provider’s stock valued at $333,000 after buying an additional 109 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

BSX has been the subject of several research reports. Stifel Nicolaus cut their price target on Boston Scientific from $110.00 to $90.00 and set a “buy” rating for the company in a research note on Friday, March 20th. Raymond James Financial restated an “outperform” rating and issued a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Barclays lowered their price objective on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 3rd. UBS Group lowered their price objective on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Finally, TD Cowen lowered their price objective on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $102.82.

Boston Scientific Stock Performance

NYSE:BSX opened at $64.28 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific Corporation has a 52-week low of $60.59 and a 52-week high of $109.50. The firm has a market cap of $95.53 billion, a price-to-earnings ratio of 33.13, a PEG ratio of 0.98 and a beta of 0.78. The business’s fifty day moving average is $69.60 and its 200 day moving average is $86.96.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the previous year, the company posted $0.70 EPS. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts are increasingly bullish, citing expectations for ~30% year‑over‑year growth in 2026 and constructive analyst commentary that supports upside to BSX’s earnings trajectory. Analysts Bullish on Boston Scientific (BSX)
• Positive Sentiment: Zacks previews point to robust cardiovascular momentum and steady MedSurg growth heading into Q1 results, implying potential upside to revenue and EPS vs. consensus if procedure trends hold. Will Robust Cardiovascular Performance Fuel BSX’s Q1 Earnings?
• Positive Sentiment: Boston Scientific is investing $88.4M to expand R&D operations in Ireland — a sign of continued product development and investment in innovation that supports medium‑term growth prospects. Boston Scientific invests $88.4M to expand R&D in Ireland
• Neutral Sentiment: Zacks also published a deeper Q1 preview on key operational metrics investors should watch (procedure volumes, segment mix, product cadence) that could swing reactions to the print beyond headline revenue/EPS. Boston Scientific (BSX) Q1 Earnings Preview
• Neutral Sentiment: Recent pieces revisiting BSX’s valuation and the impact of the Penumbra acquisition provide context on multiples and longer‑term returns; useful for investors framing position sizing but less likely to move intraday trading. A Look At Boston Scientific (BSX) Valuation
• Negative Sentiment: Multiple law firms have issued investor alerts and a class action has been filed alleging securities‑law violations for the July 23, 2025–Feb 3, 2026 period. These coordinated filings and lead‑plaintiff solicitations (with a May 4 deadline cited by several firms) are a near‑term headline risk that can pressure the stock or increase legal expenses/uncertainty. Representative notices and filings: PR Newswire: Shareholders Opportunity to Lead Securities Fraud Lawsuit Bronstein, Gewirtz & Grossman Class Action Notice Faruqi & Faruqi Deadline Reminder

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.